Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s CDE Proposes Removal of Ambroxol Inhalation Solution and Four Other Drugs

Fineline Cube Sep 19, 2023

The Center for Drug Evaluation has issued a notification concerning the Chemical Generic Drug Reference...

Company Drug

CSBIO’s Albenatide Shows Positive Results in Two Phase III Diabetes Trials

Fineline Cube Sep 19, 2023

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced encouraging results from two...

Company Drug

Sandoz Receives Positive CHMP Review for Trastuzumab Biosimilar in HER2-Positive Cancers

Fineline Cube Sep 19, 2023

Sandoz (SWX: SDZ), the generic and biosimilar drug maker set to separate from Novartis (NYSE:...

Policy / Regulatory

NMPA Drafts Quality Management Norms for Online Medical Device Sales

Fineline Cube Sep 19, 2023

The National Medical Products Administration (NMPA) has issued the “Medical Device Online Sales Quality Management...

Policy / Regulatory

NMPA Seeks Comments on Medical Device Classification Draft Proposal

Fineline Cube Sep 19, 2023

The National Medical Products Administration (NMPA) has issued a notification focusing on the definition and...

Company Drug

Gilead’s Kite CAR-T Therapy Yescarta Achieves 71% CMR in Phase II Trial for R/R LBCL Patients

Fineline Cube Sep 19, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has announced early results from a Phase II trial of...

Company Deals

Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products

Fineline Cube Sep 19, 2023

UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic...

Company Deals

Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development

Fineline Cube Sep 18, 2023

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm...

Company Drug

EMA’s CHMP Backs Enhertu for Advanced NSCLC with HER2 Mutations

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

BMS Expands Partnership with Samsung Biologics for Oncology Drug Manufacturing

Fineline Cube Sep 18, 2023

Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing...

Company Drug

EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Novartis’s Kisqali Reduces Cancer Recurrence Risk in HR+/HER2- Early Breast Cancer: Phase III Results

Fineline Cube Sep 18, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has published results from a Phase III study of...

Company

CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases

Fineline Cube Sep 18, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...

Company Deals R&D

GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models

Fineline Cube Sep 18, 2023

Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in...

Company Drug

Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors

Fineline Cube Sep 18, 2023

Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...

Company Medical Device

AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy

Fineline Cube Sep 18, 2023

Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the...

Company Deals Digital

Baidu Health Partners with HOB Biotech to Innovate Allergy Detection and Treatment

Fineline Cube Sep 18, 2023

Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in...

Company Medical Device

Tuodao Medical’s Percutaneous Puncture Surgery Robot NP100 Approved in China

Fineline Cube Sep 18, 2023

China-based surgical robot developer Tuodao Medical Technology Co., Ltd has received marketing approval for its...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Irinotecan Liposome Injection

Fineline Cube Sep 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received market approval...

Company Medical Device

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

Fineline Cube Sep 18, 2023

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

Posts pagination

1 … 465 466 467 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.